Lindon H. Young is the director of the pharmacology course in the Master of Science
in Biomedical Sciences program and teaches in selected courses in the DO program at
Dr. Young specializes in the area of cardiovascular pharmacology and has mentored numerous MS, DO/PhD students and residents from 2002 to present on various research projects that range from cellular based assays to human studies.
Dr. Young’s training has helped our students accomplish educational and research objectives, and continues to strive to improve the quality of teaching and mentorship to our Biomedical Sciences and DO students to pass standardized tests (e.g. Medical board exams) by having an integrative session that requires class participation via the use of the “clicker” system. Such a system enables us to immediately evaluate the classroom’s understanding of the pharmacology material. This system has proven to be effective and the classroom appears to enjoy the presentation of the material.
Dr. Young has also mentored PCOM residents that have been hired as clinical research associates in our myocardial I/R drug development program.
PhD, Pharmacology, Philadelphia College of Pharmacy and Science, 1998
BA, Biology/Psychology, Immaculata College, 1986
AS, Hotel/Food Service Management, Pennsylvania State University, 1980
Dr. Young is a Research Investigator at PCOM who has conducted research related to
myocardial ischemia-reperfusion (I/R) injury and to evaluate mechanisms related to
oxidative stress that initiate I/R injury. Such research would have clinical value
to heart attack and coronary bypass patients where limited pharmacological intervention
is available. He received his postdoctoral training in the laboratories of Drs Margaret
Weis and Allan Lefer where he conducted research related to myocardial I/R injury.
Thereafter, Dr. Young started his academic research career at PCOM in 2002. The first study was conducted using a broad-spectrum protein kinase C (PKC) inhibitor, Gö6983, which was shown to increase vascular nitric oxide (NO) release and inhibit leukocyte surperoxide (SO release). This tool served as an effective prognostic indicator for the general role of PKC regulation in I/R injury. Then he started to use selective PKC isoform inhibitors and activators that differentially regulate eNOS and NADPH oxidase activities as they relate to myocardial I/R. Subsequently, the remarkable results of PKC epsilon peptide inhibitor have led me to further explore the role of eNOS uncoupling as a key mechanism in myocardial I/R injury that transcends both rat and porcine species. PCOM has also been awarded US and worldwide patents regarding the PKC isoform peptide modulators such as PKC epsilon inhibitor. Dr. Young has collaborated with many other investigators both intra and extramurally on a wide array of research projects that range from evaluating the role of genetic markers in myocardial developmental biology to OMT-based research in patients.
Myocardial ischemia/reperfusion injury
Endothelial nitric oxide synthase
Vascular endothelial dysfunction
2013-2014 Professor of the Year Award presented by the PCOM DO Class of 2017.
P.C.O.M. has been granted U.S. (PKC beta II peptide inhibitor, filing date: 09/28/2007; patent awarded: 08/25/2011) and European (PKC epsilon peptide inhibitor, filing date: 12/11/2006; patent awarded: 05/10/2012) patents pertaining to the development of a preservation/perfusion solution that can be used in patients with acute coronary syndromes that include but are not limited to myocardial infarction, angina, coronary bypass/angioplasty and organ transplantation. –role on patents: Inventor
1999-2001 National Heart, Lung & Blood Institute Training Grant HL-07599NHH, National Service Research Award
Pennsylvania State Tobacco Grant 01/01/2012-12/31/2015
Title: Evaluation of tetrahydrobiopterin/dihydrobiopterin ratio in vascular injury tissues
Role on Project: Principal Investigator
In vivo and ex vivo mechanisms related to eNOS uncoupling during Reperfusion (Funded
by the National, Heart, Lung and Blood Institute of the NIH from 4/1/08 – 3/31/11
# 2 R15 HL076235-02): SFS RR4 to the NIH
Role on Project: Principal Investigator
Center for Chronic Disorders of Aging (CCDA) at PCOM Lindon Young, Ph D (PI) 01/01/2009-10/31/2010 Tetrahydrobiopterin (BH4) and dihydrobiopterin (BH2) in leukocyte-endothelium interactions by using intravital microscopy
Center for Chronic Disorders of Aging at PCOM Lindon Young, PhD (PI) 1/1/2008 12/31/2008
Administration of Protein Kinase C Beta II Inhibitor During Extracorporeal Shock Wave
Lithotripsy Reduces Free Radical Production
Role on Project: PI
Protein Kinase C isoform inhibition in cardiac ischemia/reperfusion (Funded by the
National, Heart, Lung and Blood Institute of the NIH from 3/18/04 – 2/28/07 # 1 R15
Role on Project: Principal Investigator at P.C.O.M
Proposed role of endothelial long chain fatty acyl CoA synthetase in the development
of post-menopausal hypertension (Funded by Women’s Health Research Institute, Texas
Tech University Health Sciences Center (TTUHSC) at Amarillo from 4/2004 – 3/2006)
Role on Project: Co-Principal Investigator with Margaret T. Weis (TTUHSC)